bioRxiv · 10.1101/472746
Massively parallel profiling of HIV-1 resistance to the fusion inhibitor enfuvirtide
Abstract
Resistance to enfuvirtide, the only clinically approved HIV-1 entry inhibitor, has primarily been mapped to the binding site in the N-terminal heptad repeat (NHR) of the Env transmembrane domain and a limited number of allosteric sites. To better delineate the genotypic determinants of resistance, we used deep mutational scanning to quantify how all mutations to HIV-1 Env affect enfuvirtide sensitivity. We identified numerous additional resistance mutations in the NHR and other regions of Env, including the co-receptor binding site. This complete map of resistance sheds light on the diverse mechanisms of enfuvirtide resistance and can inform clinical monitoring of patients.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Dingens, A. S., Arenz, D., Overbaugh, J., Bloom, J. D.. 2018-11-19. Massively parallel profiling of HIV-1 resistance to the fusion inhibitor enfuvirtide. https://doi.org/10.1101/472746
Cite the original work for its findings. Save a collection to share your selection of sources.